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Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) 
— How to diagnose and treat?
Karolina Pieszko1, Maciej Kuczyński2, Dawid Murawa3
Breast implant-associated anaplastic large cell lymphoma (ALCL) is a rare type of T-cell non-Hodgkin lymphoma 
arising around the capsule of breast implants. It has been diagnosed in an extremely small group of women 
with breast implants for breast reconstruction and augmentation. The pathogenesis of this disease is currently poorly 
understood, but it appears to be related to textured implants. The aim of this article is to provide patients, radiologists, 
pathologists, surgical oncologists and plastic surgeons with an evidence-based overview of the incidence, diagnosis, 
and management of BIA-ALCL according to real-world experience, because although it is very rare, early recognition 
and surgical resection is usually crucial and curative.
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Introduction
Breast implant-associated anaplastic large cell lympho-
ma (BIA-ALCL) is an uncommon entity arising primary in 
the capsule of breast prostheses. The disease represents 
only 2–3% of non-Hodgkin lymphomas and 12% of T-cell 
lymphomas. Tumors are characterized by the presence of a 
monoclonal expansion of CD30+ large anaplastic or Reed-
-Sternberg cells and are Anaplastic Lymphoma Kinase (ALK) 
negative [1].
Since 1962, silicone gel prostheses have been in use for 
esthetic operations and according to Bizjak et al. over 10 mil-
lion augmentations with implants have been performed [2]. 
The first case of BI-ALCL was only reported in 1997 [3]. 
In this article, we collected and analyzed data on BIA-
-ALCL, such as pathophysiology, risk factors, presentation,
diagnosis, treatment, outcomes and prevention. The Pub-
Med and Medline databases were searched using the fol-
lowing keywords: breast implants, lymphoma, large-cell, 
anaplastic, incidence, seroma, prognosis, algorithms, con-
sent forms. All review articles, case reports, original research 
articles, and any other articles relevant to BIA-ALCL were 
included. 
Etiology and prevalence
The association between breast implants and anaplastic 
large cell lymphoma was indicated by the Food and Drug 
Administration in the United States in 2011. The latest findings 
reveal that the organization is aware of 359 adverse events 
reports of BIA-ALCL. 232 of these have included information 
on the breast implant material (203 implants identified as 
textured, 28 as smooth, and one as “another surface”). Both 
silicone gel and saline implants have been reported in cases 
of BIA-ALCL [4]. Since then, other case reports and series have 
been published with the largest report of 173 patients from 
around the world published in 2015 by Brody et al. [5]. The 
rate of diagnosis is rising with time, which is probably because 
of the influence of increased use of implants, and increasing 
clinician awareness and education.
It is estimated, that 1–3 cases per 1,000,000 women 
with implants per year develop BI-ALCL and although the 
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rate is rare, it has been documented worldwide [6, 7]. Ho-
wever, recent reports from the Australian Therapeutic Go-
ods Administration state that the incidence of BIA-ALCL is 
significantly higher, between 1 case per 1000 and 1 case 
per 10,000 women who have breast implants in Australia 
[8]. The true incidence is unknown; it is undoubtedly incre-
asing. According to de Jong et al., the odds ratio for ALCL of 
breast developing in women exposed to breast implants is 
18.2 times greater than in those not carrying breast implants 
of any size [9]. In systematic review by Leberfinger et al., the 
mean age at onset of BIA-ALCL was 51 years, most women 
had breast implants in place for a mean of approximately 
10 years before diagnosis (8.6 years for reconstruction vs 
9.9 years for cosmetic surgery) [10]. The incidence of BIA-
-ALCL may be underestimated. It is important to determine 
risk factors and carry out more epidemiological studies 
which could be reported in a single official registry. Instead 
of defining a clear etiology of this disease, several risk factors 
are suggested and based on them some hypotheses have 
been created. 
The most common factors like the presence of a subc-
linical biofilm on the implant surface, capsular contracture, 
repeated capsular trauma, genetic predisposition, or an 
autoimmune etiology have been theorized [9]. Another 
article has also hypothesized toxic damage from the silicone 
component [11]. The immune system’s response to chronic 
inflammation surrounding the breast implant in a geneti-
cally susceptible patient may lead to genetic degeneration 
and dysplasia [1].
Nowadays, the proportion of used textured implants 
breast augmentation and reconstruction exceeds the 
number of smooth shell devices but this can not explain 
exhaustively why almost all cases of BI-ALCL have arisen in 
association with textured implants. The texture of implant 
surface varies by manufacturer, and can generally be classi-
fied as macrotextured, including polyurethane and Biocell, 
intermediate-textured or microtextured. Higher bacterial 
counts and greater T-cell response have been demonstra-
ted in association with the more aggressive macrotextured 
implants [9]. 
The implant biofilm can promote chronic T-cell activa-
tion surrounding breast implants in genetically predisposed 
women [12], which may be the inciting factor in BIA-ALCL 
development. Tissue ingrowth into the pores of textured 
implants is thought to prolong chronic inflammation and 
CD4 T-cells have been found to be the predominant cell 
type [13]. Additionally, it was demonstrated by Kadin et al. 
that patterns of cytokine and transcription factor expression 
are suggestive of a Th1 phenotype, further supporting the 
theory that BIA-ALCL may arise from chronic bacterial anti-
gen stimulation of T cells [14]. That is why it is expected that 
bacterial contamination and biofilm formation is minimized 
during surgery. In the case of capsular contracture, this has 
been achieved through the “14-point effect” [15, 16]. The 
Surgical 14-Point Plan for Breast Implant Placement pro-
posed by Adams et al. is presented in detail in Table I [17].
According to the data of reducing the number of bac-
teria around implants using this technique, it has been 
checked if aside from minimizing the occurrence of capsular 
contracture to less than 1% [18], the technique can also 
influence the incidence of BIA-ALCL. 
A prospective study has been carried out by eight plastic 
surgeons in five countries by placing about 43,000 macrote-
xtured breast implants using similar techniques. Surgeons 
adhered to at least 13 steps from the “14-Point Plan for 
Breast Implant Placement”. Respectively, mean follow-up 
Table I. The proposed Surgical 14-Point Plan for Breast Implant Placement [17]
1. Use intravenous antibiotic prophylaxis at the time of anesthetic induction
2. Avoid periareolar/transaxillary incisions; these have been shown in both laboratory and clinical studies to lead to a higher rate of contracture
3. Use nipple shields to prevent spillage of bacteria into the pocket
4. Perform careful atraumatic dissection to minimize devascularized tissue
5. Perform careful prospective hemostasis
6. Avoid dissection into the breast parenchyma
7. Use a dual-plane pocket
8. Perform pocket irrigation with correct proven betadine triple-antibiotic solution, non-betadine triple or 50% (1:1 dilution) or stronger 
povidone-iodine
9. Steps to minimize skin contamination (e.g. wipe/prep skin, barrier, sleeve)
10. Minimize implant open time and replacement of implant or sizers
11. Change surgical gloves before handling and use new or cleaned instruments and drapes
12. Avoid using a drainage tube, which can be a potential site of entry for bacteria (augmentation)
13. Use a layered closure
14. Use antibiotic prophylaxis to cover subsequent procedures that breach skin or mucosa
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was 11.7 (range, 1 to 14 years) in patients with Biocell and 
8.0 years (range, 1 to 20 years) in patients with polyurethane 
implants. For primary breast augmentation, 77.9% of all 
implants were used, followed by augmentation mastopexy 
9.9%, revision augmentation 8.2%, and breast reconstruc-
tion 4%. The capsular contracture rate was 2.2%. The expec-
ted number of the incidence of breast implant–associated 
ALCL in this study using only macrotextured breast implants 
would be between eight and nine diagnoses. However, 
there were no cases at all [17]. One may logically suspect 
that the operative technique is an important factor in the 
use of breast implants, especially those with the highest risk. 
It has been proved that a pro-inflammatory environ-
ment can cause cancer. An example can be the association 
of Helicobacter pylori  infection and gastric lymphoma. 
Recently, Hu et al., have reported an increased prevalence of 
bacteria called Ralstonia pickettii (a Gram-negative common 
contaminant of drinking water) within the microbiome of 
breast implant capsules taken from patients with BIA-ALCL 
compared to those with normal capsular contracture [19]. 
Loch-Wilkinson et al. identified a total of 55 patients 
from Australia and New Zealand between 2007 and 2016 
showed the frequency of implant types associated with 
BI-ALCL. Forty-four women had a single-implant exposure 
and the remaining eleven had a multiple-implant exposure. 
That is why a total of 75 breast implant pairs were applied 
in this retrospective study. The mean age of the patients 
was 47.1 years (range, 22.4 to 69.6 years). The mean time 
to develop BIA-ALCL from the time of the last implanta-
tion was 7.46 years (range, 0.2 to 27.0 years). All patients 
were exposed to textured implants at some point in their 
implant history. Comparative analysis showed the risk of 
developing breast implant–associated ALCL to be higher 
with Biocell textured implants followed by polyurethane 
(Silimed) textured implants. Table II presents the frequency 
of BIA-ALCL in relation to implant type according to Loch-
-Wilkinson et al. [20].
Despite published reports and study cases, according 
to the conclusions of the 2016 Aesthetic Breast Meeting in 
Milan about BI-ALCL, actual evidence does not permit esta-
blishment of any statistically significant association between 
implant, patient, surgery-related risk factors which could be 
drawn until large epidemiologic studies are conducted [21]. 
Therefore, future research is expected to determine whether 
certain patients and procedures have a predisposition to 
development of the disease.
Presentation and staging of the disease
BIA-ALCL patients typically present with malignant 
effusions associated with the fibrous capsule surrounding 
an implant (80%) or with solid capsule-related masses (20%), 
which may indicate a more aggressive clinical course [22].
These effusions are called in situ disease and are not 
a palpable breast tumor; they can be misinterpreted as a 
benign seroma due to subclinical infection. The median 
time after implantation to diagnose ALCL is 9 years (range 
from 1 to 32 years). A lower number of patients suffer from 
an infiltrative disease course, with a palpable mass around 
the capsule with or without periprosthetic effusion. This 
can be associated with lymph node and bilateral breast 
involvement, which usually means a worse prognosis, with 
disease-related mortality as high as 40% in 2 years [23]. The 
mean size of well documented breast mass associated with 
BI-ALCL is 3.5 cm [24]. 
Usually BI-ALCL cases are diagnosed during implant 
revision surgery which is performed for a late onset (more 
than 1 year). The majority of BI-ALCL cases have an indolent 
course provided adequate surgical ablation of the implant 
and surrounding capsule without systemic therapy, but the-
re have also been reported aggressive exceptions, disease 
progression, and death [25], the disease may be associated 
with local symptoms such as pain (21%), redness (14%), 
capsular contracture (7%), skin lesions (7%), and fever (7%) 
[7]. Symptoms of breast lumps, swelling or breast asymmetry 
may be also associated [25].
Clinical and pathological characteristics did not differ 
significantly between implant-exposed patients and breast-
-ALCL patients without implant exposure, except for seroma- 
associated features uniquely in patients with implants [26].
Patients with BI-ALCL or any type of lymphoma are 
traditionally staged by the 1971 Ann Arbor Classification 
presented in Table III [27]. Under this classification, near-
ly all BI-ALCL patients fall under one of two stages. The 
majority of patients (84%) were Ann Arbor stage IE or II, 
the remaining patients (16%) considered as stage IV with 
bone or muscle lesions [28]. In the other systematic review 
reported by Gidengil et al. in 2015, the most common stage 
at diagnosis is IE (61%), followed by stage IIE (11%). For the 
rest of patients, staging information in this study remains 
unknown [29].
Table II. Frequency of implant types associated with breast implant-
associated ALCL [14]
Texture Type Manufacturer No. (%)
Biocell (salt loss) Allergan/Inamed/McGhan 44 (58.7)
Polyurethane Silimed 14 (18.7)
Salt loss Nagor 5 (6.7)
Polyurethane Surgitek 1 (1.3)
Siltex Mentor 5 (6.7)
PIP PIP 2 (2.7)
Smooth Mentor 2 (2.7)
Smooth Unknown 2 (2.7)
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Breast implant-associated anaplastic large cell lymphoma 
behaves more like a solid tumor than a lymphoma. Therefore, 
Clemens et al. proposed using TNM staging, typically used for 
solid tumors, instead of the Ann Arbor staging classification. 
The specific surgical and pathologic BIA-ALCL staging 
system, modeled after the American Joint Committee on 
Cancer TNM system is presented in Table IV. It divides pa-
tients into a very low risk group confined to the effusion 
or a layer on the luminal side of the capsule (stage I) and 
a higher risk group with an extra-luminal spread, a breast 
mass or distant metastases which need more aggressive 
systemic treatment. Patients with stage II are locally ad-
vanced and with stage III/IV disease appear regional and 
distant spread [7].
This staging differs from the commonly used Ann Arbor 
staging and appears to predict overall survival more accura-
tely than the Ann Arbor system. Moreover, BI-ALCL seems to 
behave more similarly to other breast malignancies than to 
lymphomas with regard to the treatment, including surgical 
excision, and the clinical course of the disease [7].
Diagnosis
Diagnosis is made by the finding of abnormal cells in the 
aspirate or biopsy accompanied by the hallmark uniform 
over-expression of CD30 and negative staining for Anapla-
stic Lymphoma Kinase (ALK).
Clemens et al. [30] have described some specific criteria 
for diagnosis of breast implant-associated anaplastic large 
cell lymphoma such as:
1. Adequate specimen of a tumor, involving an effusion 
surrounding a breast implant
2. Large lymphoid cells with abundant cytoplasm and 
pleomorphic nuclei
3. T-cell markers with uniform expression of CD30 by im-
munohistochemistry or flow cytometry 
4. Negative for anaplastic lymphoma kinase (ALK) protein 
or translocations involving the ALK gene at chromosome 
2q23 
For suspected patients, any aspiration of periprosthetic 
fluid should be sent to pathology for cytologic evaluation 
through fine-needle aspiration, flow cytometry, and CD30 
Table III. Ann Arbor staging system
Staging Description
Stage I Involvement of a single lymph node region or single lymphoid structure, such as spleen, thymus or Waldeyer ring (I), or a single 
extranodal site (IE)
Stage II Involvement of two or more lymph node regions or lymphoid structures on the same side of the diaphragm (II) or localized 
involvement of an extralymphatic site and one or more lymph nose regions on the same side of the diaphragm (IIE)
Stage III Involvement of lymph nodes regions or lymphoid structures on both sides of the diaphragm (III), which can also be accompanied 
by localized involvement of an extralymphatic site (IIIE), or spleen (IIIS) or both (IIISE)
Stage IV Diffuse or disseminated involvement of one or more extralymphatic organs or tissues with or without associated lymph node 
enlargement
Table IV. The proposed TNM Staging for Breast Implant-Associated Anaplastic Large-Cell Lymphoma [20]
TNM or Stage Designation Description
T: tumor extent T1 Confined to effusion or a layer on luminal side of capsule
T2 Early capsule infiltration
T3 Cell aggregates or sheets infiltrating the capsule
T4 Lymphoma infiltrates beyond the capsule
N: lymph node  N0 No lymph node involvement
N1 One regional lymph node (+)
N2 Multiple regional lymph nodes (+)
M: metastasis M0 No distant spread
M1 Spread to other organs/distant sites
Stage IA T1N0M0
Low risk groupIB T2N0M0
IC T3N0M0
IIA T4N0M0
High risk group
IIB T1-3N1M0
III T4N1-2M0
IV TanyNanyM1
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immunohistochemistry of effusion including a clinical 
history with the stated intent to “rule out BI-ALCL”. Pathologic 
evaluation may demonstrate BI-ALCL as individual cells, 
cell clusters in aggregates, or as cohesive sheets. Diagnosis 
using Wright-Giemsa or hematoxylin and eosin staining 
alone is usually insufficient, however BI-ALCL will demon-
strate strong and uniform membranous expression of CD30 
immunohistochemistry [13]. 
Ultrasound may help define the extent of an effusion 
and can be helpful in identifying any associated capsule 
masses. Included in clinical examination should be evalu-
ation of regional lymph nodes. The volume of an effusion 
can range from 50 to 1,000 mL and is typically more viscous 
than a benign seroma owing to the high protein content 
and cellularity. The surrounding capsule may be thickened 
and fibrous or may be deceptively unremarkable on gross 
examination consistent with the under-appreciation of this 
lymphoma. If a mass is present, it can protrude outward into 
the soft tissue or into the implant creating a mass effect 
distortion on imaging [5].
Adrada et al. reviewed 44 breast implant-associated ALCL 
cases according to radiologic imaging features and made a 
comparison according to image sensitivity and specificity of 
specific methods presented in Table  V. Thus, it is recommen-
dable to use ultrasound as a screening tool and for some cases 
also MRI or PET to determine extension and for surveillance 
of disease. In regard to mammography, its sensitivity was 
reported as insufficient for BI-ALCL effusion and mass [31].
Management and treatment
Mostly patients have slow disease progression and 
a  good prognosis but it is important to pay attention in 
the case of occasional lymphadenopathy and metastases, 
which need also some adjuvant medical therapies.
According to two recommended management algo-
rithms for BIA-ALCL in the USA and the UK [6, 30], doctors 
should diagnose and examine those patients presenting 
symptoms like sudden, unexplained effusion, new painful 
mass around or involving an implant capsule, especially at 
least one year after implant insertion. 
Usually it is advisable to use ultrasounds for breast and 
ipsilateral lymph nodes. Moreover, it is mentioned in the 
English algorithm to use mammogram, if there is residual 
breast tissue and in the American algorithm to use MRI if 
ultrasound is inconclusive. 
In a case of effusion, it is recommendable to proceed 
with fine needle aspiration cytology (FNAC) of total effusion 
volume. This is different to presentation of a mass, which 
needs needle core biopsy (NCB) of the mass and or without 
abnormal axillary lymph nodes, followed by oncologic con-
sultation. The next step is to diagnose all types of specimens 
using cytology, histology, flow cytometry and checking 
CD30 cells. Upon confirming histologically BIA-ALCL, ana-
plastic lymphoma kinase (ALK) negative, CD30 positive cells, 
it is crucial to report BIA-ALCL to the PROFILE Registry.
After reporting it is advisable to discuss the case within 
a multidisciplinary team consisting of a plastic surgeon, 
a surgical oncologist, an oncologist and a pathologist. 
Lymphoma staging is very important for choosing the 
best treatment for the patient; this can be determined by 
PET, CT scan or bone marrow biopsy. 
Patients with stage I (localized disease) are treated with 
implant removal and total capsulectomy. Those presenting 
stage II, III, IV (advanced disease), besides surgical treatment 
with mass and nodes excision with total capsulectomy and 
explantation, also need some adjuvant therapies, like che-
motherapy or immunotherapy as decided by the multidi-
sciplinary team [6, 30]. 
Standard chemotherapy regimens used in the mana-
gement of systemic ALCL are anthracycline-based, such as 
cyclophosphamide, doxorubicin, vincristine and predni-
solone (CHOP). This treatment seems to be more effective 
in patients with ALK-positive systemic ALCL when compa-
red to ALK-negative disease (5-year survival rates of 70 to 
90% vs 40 to 60%). In patients with ALK negative systemic 
disease, CHOP may be ineffective. Other regimens may be 
used and remissions consolidated with autologous stem 
cell transplantation [25]. 
Clinical trials assessing the use of Brentuximab Vedotin, 
is a novel anti-CD30 monoclonal antibody that has impro-
ved the management of ALK-negative systemic ALCL with 
a reported objective response rate of 86% and complete 
remission rate of 59% in relapsed or refractory systemic 
ALCL [32].
Table V. Comparison of imaging sensitivity and specificity of specific methods [23]
RADIOLOGIC IMAGING 
FEATURES
EFFUSION BI-ALCL MASS
sensitivity specificity sensitivity specificity
Ultrasound 84% 75% 46% 100%
Computerized Tomography 55% 83% 50% 100%
Magnetic Resonance Imaging 82% 33% 82% 33%
Positron Emission Tomography 38% 83% 64% 88%
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Recently, Fleming et al. described two interesting cases 
of documented evidence of spontaneous regression and 
spontaneous resolution of confirmed BIA-ALCL. The first 
patient, due to enlargement of the breast (after breast im-
plant augmentation in 1994 and 2009), underwent aspi-
ration, the cytology of which was diagnostic for BIA-ALCL 
with abundant atypical T cells that were CD30+ and ALK–. 
After two months, the aspiration was repeated and most 
of the cells identified were benign macrophages and flow 
cytometry was normal. The second case is a patient who 
underwent an uncomplicated primary breast augmentation 
in submuscular pockets in May 2013, and in February 2017 
complained of a sudden enlargement of her breast. At the 
beginning, cytology and immunohistochemistry confirmed 
BIA-ALCL with atypical T cells which were CD30+ and ALK–. 
Next, she had a bilateral explantation and capsulectomies in 
May 2017, but cytology, flow cytometry and immunohisto-
chemistry of a small residual fluid collection, and histopatho-
logy of the capsule, showed no evidence of malignancy. This 
not only proves that the disease can spontaneously resolve 
but also that it can do so rapidly. Nevertheless, given the 
potentially fatal consequences of inadequate treatment, 
and the present inability to be certain that the disease is 
not invasive without histopathology, bilateral explantation 
and capsulectomy should remain the current recommended 
minimum treatment [33].
Conclusions
The aim of this article was to raise awareness through 
education and better information about BIA-ALCL. It is cru-
cial to remember that each seroma occurring more than 
1 year after implantation not confirmed by infection or trau-
ma should be considered as suspicious for disease. However, 
we should remember that many benign causes for the sud-
den development of peri-implant fluid exist and these are 
the majority compared to BIA-ALCL. It is recommended that 
cases are managed in specialist tertiary centers which have 
the appropriate experience in the management of the dise-
ase. In the BIA-ALCL context, although the risk is extremely 
low, it is nevertheless doctors’ duty to provide information to 
all patients considering breast implant surgery and include 
BIA-ALCL among possible complications in the informed 
consent form. The American Society of Plastic Surgeons 
prepared an example of such a document, which is available 
for download from their website: www.plasticsurgery.org. 
Moreover, according to the recommendation of the con-
sensus established during the Maurizio Bruno Nava (MBN) 
2016 Aesthetic Breast Meeting, all confirmed BIA-ALCL cases 
should be reported to the Patient and Outcomes for Breast 
Implants and Anaplastic Large Cell Lymphoma Etiology and 
Epidemiology and to the respective competent authorities 
that regulate or guarantee the safety of medical devices [21]. 
Undoubtedly, current knowledge about BIA-ALCL patho-
genesis, diagnostic pathways, prognosis, and therapeutic 
options is limited. Therefore, reporting and more analytical 
epidemiologic studies will provide better evidence on the 
disease in the future. 
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